<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278144</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-20201001</org_study_id>
    <nct_id>NCT04278144</nct_id>
  </id_info>
  <brief_title>A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors</brief_title>
  <official_title>Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bolt Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bolt Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in&#xD;
      HER2 expressing advanced malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has four parts. Part 1 is a dose escalation of BDC-1001 as a single agent to&#xD;
      determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), or maximum&#xD;
      protocol dose (MPD) recommended for Part 3. In Part 3, the selected dose will be administered&#xD;
      as monotherapy to patients with selected advanced malignancies. Part 2 is a dose escalation&#xD;
      of BDC-1001 in combination with nivolumab to determine the maximum tolerated dose (MTD),&#xD;
      recommended Phase 2 dose (RP2D), or maximum protocol dose (MPD) recommended for Part 4. In&#xD;
      Part 4, the selected dose will be administered in combination with nivolumab to patients with&#xD;
      selected advanced malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple ascending dose and dose-expansion of BDC-1001 administered as a single agent or in combination with nivolumab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities (DLTs)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Escalation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of potential-immune related toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerable dose (MTD) or a tolerated dose below MTD</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)</measure>
    <time_frame>2 years</time_frame>
    <description>Expansion period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK (Cmax) of BDC-1001 as a single agent and in combination with nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (Cmin) of BDC-1001 as a single agent and in combination with nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (AUC0-t) of BDC-1001 as a single agent and in combination with nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (AUC0-inf) of BDC-1001 as a single agent and in combination with nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (CL) of BDC-1001 as a single agent and in combination with nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (Vz) of BDC-1001 as a single agent and in combination with nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (t1/2) of BDC-1001 as a single agent and in combination with nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) using RECIST 1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) of confirmed CR, PR, or stable disease (SD) lasting 4 or more weeks</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-BDC-1001 antibodies</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>Expansion period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of potential-immune related toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Expansion period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>HER2 Positive Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Single agent BDC-1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination BDC-1001 plus nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDC-1001</intervention_name>
    <description>Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist</description>
    <arm_group_label>Combination BDC-1001 plus nivolumab</arm_group_label>
    <arm_group_label>Single agent BDC-1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Programmed death receptor-1 (PD 1)-blocking antibody</description>
    <arm_group_label>Combination BDC-1001 plus nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have an advanced solid tumor with documented HER2-protein expression or&#xD;
             gene amplification for which approved therapies have been exhausted or are not&#xD;
             clinically indicated.&#xD;
&#xD;
          -  Measurable disease as determined by RECIST v.1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Tumor tissue (archival or collected prior to the study start) available for&#xD;
             exploratory biomarker evaluation.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of severe hypersensitivity to any ingredient of the study drug(s), including&#xD;
             trastuzumab or other monoclonal antibody.&#xD;
&#xD;
          -  Previous treatment with a TLR 7, TLR 8 or a TLR 7/8 agonist.&#xD;
&#xD;
          -  Impaired cardiac function or history of clinically significant cardiac disease&#xD;
&#xD;
          -  Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or&#xD;
             hepatitis C infection.&#xD;
&#xD;
          -  Active SARS-CoV-2 infection&#xD;
&#xD;
          -  Untreated central nervous system (CNS), epidural tumor or metastasis, or brain&#xD;
             metastasis.&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amreen Husain, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bolt Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bolt Biotherapeutics</last_name>
    <phone>1-650-665-9295</phone>
    <email>info@boltbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Kimbell, RN</last_name>
      <phone>520-668-5678</phone>
      <email>stacey.kimbell@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace A Castaneda</last_name>
      <phone>650-721-4076</phone>
      <email>annabelc@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wagner, RN</last_name>
      <phone>202-687-9782</phone>
      <email>sw1095@georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Intake</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DFCI Clinical Trials Hotline</last_name>
      <phone>877-338-7425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karie Gignac, RN</last_name>
      <phone>313-695-9808</phone>
      <email>Kgignac1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski</last_name>
      <email>kathy.estkowski@startmidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology (NYOH)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josephine Faruol</last_name>
      <phone>518-489-3612</phone>
      <phone_ext>1014</phone_ext>
      <email>josephine.faruol@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-888-4201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phase I Referrals</last_name>
      <email>phaseI-referrals@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ecaterina I Dumbrava, MD</last_name>
      <phone>713-563-1930</phone>
      <email>EEIleana@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@startsa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira, MD, PhD, FACP</last_name>
      <phone>703-280-5390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeeyun Lee, MD</last_name>
      <phone>+82-2-3410-1754</phone>
      <email>jyunlee@skku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Wook Lee, MD, PhD</last_name>
      <phone>+82-31-787-7037</phone>
      <email>hmodoctor@snubh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <phone>+82-2-3010-3230</phone>
      <email>ykkang@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>ERBB2</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastroesophageal junction</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Biliary Tract Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Urothelial Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>TLR7/8 agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

